The Cogent Team recognized Cholangiocarcinoma Awareness Month by going green in their sweatshirts from the Cholangiocarcinoma Foundation (CCF). We are committed to supporting those affected by Cholangiocarcinoma and working together with Patient Advocacy Groups like CCF to create meaningful change for this community by advancing science through our clinical program for FGFR.? #GreenforCCA?#CholangiocarcinomaAwarenessMonth?#WorldCCADay
Cogent Biosciences
生物技术研究
Waltham，Massachusetts 12,306 位关注者
Precision therapeutics for genetically defined diseases. Real solutions for real challenges.
关于我们
Cogent Biosciences is a biotechnology company focused on developing novel precision therapies to treat a broad range of patients with unmet medical needs. Cogent’s lead program, bezuclastinib, is designed to selectively and potently inhibit exon 17 mutations found within the KIT receptor tyrosine kinase, including KIT D816V. KIT D816V is responsible for driving a rare and serious condition called Systemic Mastocytosis, and exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. Bezuclastinib has already exhibited promising early clinical activity and safety in a Phase 1/2 trial in patients with advanced GIST and also has the potential to fill an unmet need for patients living with Systemic Mastocytosis.
- 网站
-
https://www.cogentbio.com
Cogent Biosciences的外部链接
- 所属行业
- 生物技术研究
- 规模
- 51-200 人
- 总部
- Waltham，Massachusetts
- 类型
- 上市公司
- 创立
- 2014
- 领域
- gastrointestinal stromal tumors (GIST)、Oncology、Systemic Mastocytosis和kinase inhibitors
地点
Cogent Biosciences员工
动态
-
Today we released our fourth quarter and full year financial results and recent business highlights and reiterated our anticipated milestones. Our progress in 2024 underscores the positive momentum we're carrying into 2025. Learn more here:?https://bit.ly/41hAV8k
-
-
We're participating in the?Guggenheim SMID Cap Biotech?Conference next week. Listen to the analyst-led fireside discussion on Wednesday, February 5th at 9:30 a.m. ET. Register for the webcast here:?https://bit.ly/427oSNa
-
-
This morning, we announced our 2025 planned milestones for bezuclastinib and our emerging research pipeline. With topline results expected from three registration-directed trials, 2025 is going to be transformational. Read more https://bit.ly/4hfGlr3and and listen to our CEO Andrew Robbins present a company overview at #JPM25 tomorrow, Tuesday, January 14 here bit.ly/427oSNa
-
-
Our CEO, Andrew Robbins, will present at #JPM25 on Tuesday, January 14th, at 7:30 am PT/10:30am ET. Tune in to the live webcast here https://bit.ly/427oSNa
-
-
We’re proud to share our latest data with bezuclastinib from SUMMIT today. The data highlight rapid and sustained symptomatic improvement in #NonAdvSM patients and continue to support our belief that bezuclastinib has the potential to be a best-in-class treatment option. We’re grateful to the patients, physicians and families who helped us enroll this trial so quickly and look forward to sharing topline results in July 2025. Read the full press release here https://bit.ly/41mNQaH and listen to today’s webcast here https://bit.ly/49s7F2o
-
-
Today we reported positive updated clinical data from our ongoing Phase 2 APEX trial with bezuclastinib in #AdvSM. Read the update https://bit.ly/3D6oqEg and tune in to our webcast tomorrow morning at 8am ET/5am PT https://lnkd.in/eNSK_-Rj
-
-
The Cogent team is in San Diego for #ASH24. We’re looking forward to engaging with the #hematology community and sharing our latest updates with bezuclastinib from our APEX and SUMMIT trials. Find us at booth #2804 to learn more about our programs and our commitment to improving the lives of people living with #AdvSM #NonAdvSM #raredisease.
-